In vitro work has shown that proliferative growth in ATRT and synovial sarcomas is dependent on residual GBAF functional activity and hence targeting selective subunits of the GBAF subcomplex; namely, BRD9 or GLTSCR1 can reduce cellular viability in these solid tumors [20,36]. This evidence concerns the gene BRD9 and synovial sarcoma.